New Topical Biosimilar & Biobetter R&D Pipeline Study by FirstWord Now Available at MarketPublishers.com

New research study “Charting the Biosimilar and Biobetter Development Pipeline” drawn up by FirstWord has been recently published by Market Publishers Ltd.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
TD The Market Publishers Ltd

http://marketpublishers.com/

London, UK (PRWEB) September 24, 2012

When is the earliest potential launch for “Biosimilar X”? What biosimilars are being developed in each therapeutic area, drug class, and compound class? Which reference products are most targeted by biosimilar and biobetter developers? Is the reference product sales value the key factor shaping biosimilar development priorities? Which therapy areas are going to experience the most and fewest biosimilar entries? Which companies are most active in the biosimilar and biobetter arena? Which biosimilar companies have been most successful in getting their products onto the market? How many new biosimilars will be on the market by 2014?

All these questions and a lot more burning issues are discussed within the new research study “Charting the Biosimilar and Biobetter Development Pipeline” drawn up by FirstWord and recently published by Market Publishers Ltd.

Report Details:

Title: Charting the Biosimilar and Biobetter Development Pipeline
Published: September, 2012
Pages: 428
Price: US$ 1,950.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/charting-biosimilar-n-biobetter-development-pipeline.html

The research study provides an in-depth understanding of the universe of biosimilar and biobetter development.

Key Report Features:

  •     over 60 exclusive tables and charts, offering a view of the biosimilar pipeline;
  •     details of all biosimilars/biobetters in development in US and EU markets, with their development status and earliest potential launch dates;
  •     information on international biogenerics that may seek approval as biosimilars/biobetters in US and EU markets;
  •     list of reference products, with key sales data and expected patent expiration dates;
  •     detailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound class;
  •     reports showing the most active companies, regions, and countries;
  •     insights into areas of most intense competition and greatest potential opportunity;
  •     concise commentary highlighting key findings, and providing valuable market intelligence;
  •     definitions of key terms and concepts.

Report Contents:

Executive Summary

Introduction

Definitions and Methodology

Scope and coverage
Glossary
Methodology
Patents
Indexing by indication
Indexing by phase of development
Nomenclature

Reference Products

Top20 Reference Products

Biosimilars in Development

Biosimilars by earliest potential launch date — US & EU
Biosimilars by class and earliest potential launch date in the US (total number)
Biosimilars by class and earliest potential launch date in the EU (total number)
Biosimilar developers countries and regions
Biosimilars in development by drug class
Leading biosimilar companies - number of biosimilar products in portfolio
Biosimilar development pipelines by compound class and therapy area

Biosimilar Development Pipelines by Compound Class

Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietin

G-CSF

Insulins
Other Hormones (excluding insulins)

Biosimilar Development Pipelines by Therapy Area

Endocrine and metabolic disorders
Haematology
Infectious and Parasitic Disease
Musculoskeletal disorders
Neurology
Neuromuscular diseases
Obstetrics/gynaecology
Oncology
Ophthalmology

Biobetters in Development

Biobetter developments by compound class and therapy area
Biobetter development by therapy area and stage
Biobetters by class and earliest potential launch in the US
Biobetters by class and earliest potential launch in the EU
Biobetter developers by compound class

Biobetter Development Pipeline by Compound Class

Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietins
Others (Enzymes, Blood Clotting Factors)
Other Hormones (excluding insulins)

Biobetter Development Pipeline by Therapy Area

Autoimmune disease
Autoinflammatory disease
Cardiovascular diseases
Dermatology
Endocrine and metabolic disorder
Haematology
Infectious and parasitic disease
Musculoskeletal disorders
Neurology
Obstetrics/gynaecology
Oncology
Respiratory disease
Wound care

Product Profiles

More new research studies by the publisher can be found at FirstWord page.


Contact